Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
2 Months : From Nov 2019 to Jan 2020
By Michael Dabaie
Gilead Sciences Inc. (GILD) said its Kite subsidiary had positive findings from real-world use of Yescarta in relapsed or refractory large B-Cell lymphoma.
Kite and the Center for International Blood and Marrow Transplant Research unveiled the findings from an ongoing post-marketing study evaluating the safety and efficacy of Yescarta in adult patients.
In the analysis, efficacy and safety of Yescarta were comparable to that observed in the ZUMA-1 trial, despite a larger proportion of older, more difficult-to-treat patients in the real-world setting, Gilead said.
Yescarta was approved by the U.S. Food and Drug Administration in 2017 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
December 09, 2019 15:28 ET (20:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.